How Unbranded Websites Can Extend Brand Reach throughout the Patient Life Cycle?

Manhattan ResearchConsumer reliance on condition-focused content during the disease research process, growing emphasis on customer care throughout the treatment continuum, and uncertainty around the DTC regulatory environment is prompting increased interest in unbranded online initiatives. Manhattan Research releases a new report, "Unbranded Websites: Extending Brand Reach throughout the Patient Life Cycle", to support pharma marketers and their agencies with key data, insights, and strategic considerations as they approach unbranded online investments. The report discusses the market potential for unbranded websites, how strong of an opportunity unbranded initiatives represent for pharma, the elements consumers seek on these properties, and best practices for marketers to consider.

"The extent to which a company can benefit from unbranded strategies varies greatly by disease category and product situation, among other issues, but under the right circumstances, this type of investment can support lead generation, relationship marketing, and awareness and education initiatives," said Maureen Malloy, Healthcare Marketing Analyst and lead author of the report. "A recent warning letter sent about two Novartis unbranded websites will likely lead to a more conservative approach by most brands."

"Unbranded Websites" draws from Manhattan Research's ePharma Consumer® v9.0 study conducted in Q4 2009 among 6,575 adults (age 18+). For more information about the report and an excerpt, please visit http://www.manhattanresearch.com/unbranded-websites.

Report Topics

Title: Unbranded Websites: Extending Brand Reach throughout the Patient Life Cycle

  • Landscape: Unbranded Websites and Consumer Trends
    • Consumer Demand and Market Potential for Unbranded Online Initiatives
    • Profiling Unbranded Website Users
  • Outlook: Implement Unbranded Initiatives Strategically
  • Best Practices and Examples

About ePharma Consumer® v9.0
ePharma Consumer® v9.0 is focused on the attitudes and behaviors of consumers seeking pharmaceutical information online. The study was conducted via online survey in Q4 2009 among 6,575 adults (age 18+). ePharma Consumer® also provides data on more than 160 pharmaceutical product websites. Clients can segment the broad market research to provide in-depth data on more than 80 condition groups. For additional product and subscription information, please visit http://www.manhattanresearch.com/epc.

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a leading market research and advisory services firm for global pharmaceutical and healthcare companies. For more information, visit http://www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.decisionresourcesinc.com.

Most Popular Now

Aspirin green light for brain bleed stroke patient…

People who suffer a stroke caused by bleeding in the brain - known as brain haemorrhage - can take common medicines without raising their risk of another stroke, a major ...

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

APRINOIA Therapeutics awarded grant from The Micha…

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that...

Benralizumab not effective reducing exacerbations …

More than 15.3 million people in the U.S. suffer from chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in this country, according t...

Pfizer announces top-line results from Phase 3 Tri…

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age wi...

Novartis phase II data for new inhaled combination…

Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol ac...

New data show Symbicort reduces attacks in mild as…

New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol)...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...

Roche's personalised medicine entrectinib shrank t…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced positive data from the Phase I/II STARTRK-NG study, evaluating the investigational medicine entrectinib in children and adole...